Joint (JYNT) AI Stock Analysis

• Market Cap: $133.50M
• Dividend Yield: N/A
• Average Volume (3M): 133.85K
• Price to Earnings (P/E): 71.0
• Beta (1Y): 1.01
• Revenue Growth: -54.93%
• EPS Growth: N/A
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 14,866,192
• 10 Day Avg. Volume: 93,155
• 30 Day Avg. Volume: 133,848
• PEG Ratio: 1.36
• Price to Book (P/B): 8.85
• Price to Sales (P/S): 3.06
• P/FCF Ratio: 19.27
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 81.93
• Enterprise Value/Gross Profit: -11.70
• Enterprise Value/Ebitda: -82.55
• 1Y Price Target: $11.33
• Price Target Upside: 26.17% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $9.00 ▲(0.22% Upside)

The score is primarily weighed down by weak and unstable recent fundamentals, including an extreme TTM revenue decline and losses, partially offset by low leverage and still-positive cash generation. Technicals are modestly improving short-term but remain weak longer-term, while valuation is demanding with a high P/E. The latest earnings call adds some support via improving EBITDA, strong cash, and buybacks, but guidance and sales trends remain mixed.

Positive Factors

Low leverage / strong balance sheet

Persistently low debt ratios give the company durable financial flexibility, lowering refinancing and interest-rate risk. This supports strategic execution—refranchising, opportunistic M&A, and buybacks—without over-reliance on external funding, strengthening long-term resilience.

Positive operating and free cash flow

Sustained positive operating and free cash flow, even amid volatility, indicates the business can generate internal liquidity to fund operations, marketing and refranchising. Continued cash generation underpins strategic initiatives and reduces dependence on external capital over months.

Improving profitability and strong cash/buybacks

Material EBITDA improvement and a sizable cash balance alongside active buybacks signal operational progress and management confidence. Strong liquidity and capital returns capacity provide optionality to support marketing, tech investment, or continued refranchising over the medium term.

Negative Factors

Severe TTM revenue collapse

An extreme contraction in trailing revenues undermines scale economies and margin sustainability, making fixed-cost absorption and long-term profitability recovery more difficult. Such a structural revenue drop impairs forecast visibility and stresses the business model over coming quarters.

Sharp free cash flow deterioration

A steep FCF decline and year-to-year volatility weaken the company’s ability to consistently fund growth, refranchising costs, or cushion demand shocks. Even with positive levels, deteriorating cash momentum raises execution risk and limits durable reinvestment capacity.

Weakening demand metrics and guidance

Declines in system-wide sales, comp trends and new patient acquisition point to structural demand headwinds in the core market. Persistent softening in customer flow reduces revenue visibility, inhibits margin leverage, and constrains sustainable top-line recovery absent lasting marketing or product gains.

Joint Business Overview & Revenue Model

Company Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

How the Company Makes Money

Joint generates revenue through the sale of its dietary supplements and joint health products, which are distributed via various channels including e-commerce platforms, retail partnerships, and direct-to-consumer sales. The company has established key partnerships with health and wellness retailers, enabling broader market access and visibility for its products. Additionally, Joint may engage in subscription models for ongoing customer purchases, providing a steady revenue stream. The company's marketing strategies, including influencer partnerships and targeted advertising, contribute to customer acquisition and brand loyalty, further enhancing its earnings potential.

Joint Financial Statement Overview

Summary

Joint faces challenges with profitability and cash flow sustainability despite maintaining reasonable margins and low leverage. The decline in revenue and equity over recent periods highlights potential financial instability, and consistent net losses are a significant concern for future growth.

Income Statement

The company has seen fluctuating revenue with a notable decline from 2023 to TTM (Trailing-Twelve-Months). Gross profit margin remains strong at approximately 63.5% for TTM. However, the consistent negative EBIT and net loss indicate ongoing operational challenges and profitability issues, as evidenced by negative net profit margins.

Balance Sheet

The balance sheet shows reasonable stability with a debt-to-equity ratio of about 0.11 in TTM, indicating low leverage. However, the decline in equity over the years and the low return on equity due to negative net income suggest potential financial stress. The equity ratio stands at 25.8%, showing moderate reliance on equity financing.

Cash Flow

Cash flow analysis shows positive operating cash flow, but decreasing over the periods. Free cash flow is positive but has been inconsistent, reflecting challenges in maintaining cash generation. The operating cash flow to net income ratio is negative due to consistent net losses, highlighting potential cash flow sustainability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44M	52.16M	46.98M	101.25M	80.01M	58.68M
Gross Profit	-10.11M	40.65M	36.50M	92.08M	72.35M	52.18M
EBITDA	-1.43M	2.90M	8.88M	7.89M	10.07M	8.18M
Net Income	-799.12K	-5.80M	-9.75M	626.71K	7.57M	13.17M
Balance Sheet
Total Assets	69.39M	83.15M	87.21M	93.49M	87.06M	65.88M
Cash, Cash Equivalents and Short-Term Investments	30.71M	25.05M	18.15M	9.75M	19.53M	20.55M
Total Debt	2.09M	795.03K	2.86M	26.06M	23.62M	18.48M
Total Liabilities	46.66M	62.48M	62.44M	60.90M	56.75M	44.75M
Stockholders Equity	22.70M	20.65M	24.75M	32.56M	30.28M	21.13M
Cash Flow
Free Cash Flow	1.63M	8.23M	9.68M	2.31M	6.85M	8.03M
Operating Cash Flow	3.07M	9.42M	14.68M	8.21M	13.84M	11.18M
Investing Cash Flow	6.52M	-631.55K	-6.19M	-17.90M	-12.75M	-4.60M
Financing Cash Flow	-873.09K	-2.00M	174.12K	328.61K	-2.00M	5.60M

Joint Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.98
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JYNT, the sentiment is Positive. The current price of 8.98 is above the 20-day moving average (MA) of 8.87, above the 50-day MA of 8.50, and below the 200-day MA of 10.04, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 57.75 is Neutral, neither overbought nor oversold. The STOCH value of 70.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JYNT.

Joint Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	74 Outperform	$2.00B	20.02	9.94%	1.80%	23.74%	-18.99%
USPH	63 Neutral	$1.24B	35.32	7.30%	2.25%	17.50%	154.28%
ASTH	61 Neutral	$1.42B	148.53	1.29%	―	68.17%	-85.42%
TOI	52 Neutral	$424.02M	-6.70	-3407.86%	―	21.67%	16.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JYNT	49 Neutral	$133.50M	70.99	-1.37%	―	-54.93%	―

Joint Corporate Events

Joint Reaches Governance Agreement With Bandera Partners

On January 5, 2026, Joint entered into a letter agreement with Bandera Partners LLC and Jefferson Gramm that provides for Mr. Gramm to be included in the company’s slate of director nominees at its 2026 annual meeting of stockholders and for the board to recommend that shareholders vote in favor of his election. The agreement, which imposes voting commitments, standstill obligations, and transfer restrictions on Bandera’s holdings of Joint’s common stock, is set to remain in effect until the earlier of thirty days before the director-nomination deadline for the 2027 annual meeting or January 21, 2027, signaling a negotiated governance arrangement with an important shareholder through that period.

The most recent analyst rating on (JYNT) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Terminates Southern California Clinics Sale

On December 5, 2025, The Joint Corp. entered into an Asset Purchase Agreement to sell 22 company-owned or managed clinics in Virginia, North Carolina, and South Carolina to a group of buyers for approximately $1.5 million. The transaction, which involves existing franchise community members, is expected to enhance the company’s strategic initiatives and growth. Additionally, on December 11, 2025, The Joint Corp. terminated a previous agreement to sell 45 clinics in Southern California due to the buyer’s failure to meet closing conditions, with no penalties incurred.

The most recent analyst rating on (JYNT) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Corp. Sells Clinics in $4.5M Deal

On November 2, 2025, The Joint Corp. entered into an Asset Purchase Agreement with Elite Chiro Group to sell the assets of 45 clinics in Southern California for $4.5 million. This transaction includes franchise rights and is subject to certain conditions, including lease assignments and customary closing conditions. Additionally, The Joint Corp. has been authorized to repurchase an additional $12 million of its stock, reflecting confidence in its growth and profitability strategies. The company reported a 6% revenue increase in Q3 2025 compared to Q3 2024, with significant improvements in net income and adjusted EBITDA, despite a slight decline in system-wide sales.

The most recent analyst rating on (JYNT) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.